



**Eisai Co., Ltd.**

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

*Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.*

---

No. 08-59

**FOR IMMEDIATE RELEASE**

November 11, 2008

**Eisai Completes Alliance Agreement with TorreyPines Therapeutics  
for Genetic Research Programs to Discover Genes Associated with LOAD  
-New Agreement Signed for Eisai to Purchase Research Assets-**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced the completion of research alliance agreements that have been signed with TorreyPines Therapeutics, Inc. (Headquarters: California, USA, Acting CEO: Evelyn Graham) since 2002 for the discovery of genes associated with late onset Alzheimer's disease (LOAD). Following the completion, the companies signed a new agreement in which Eisai will purchase all research data and assets obtained from such research activities conducted by TorreyPines Therapeutics.

The new agreement was based on the two consecutive research activities conducted by TorreyPines Therapeutics: the research focusing on the discovery of genes responsible for LOAD conducted from October 2002 to September 2005, and the genetic research program, focusing on unbiased genome-wide screening, to unveil the whole picture of the pathogenesis of the disease conducted from October 2005 to September 2008. With the new agreement, Eisai will purchase all research data and assets obtained from such research activities.

With these research data and assets, Eisai will continue to advance its research activities in order to create a next generation treatment for Alzheimer's disease that is based on genetic information.

**Contact:**

PR Department  
Eisai Co., Ltd.  
03-3817-5120